Escitalopram oxalate - Isotope Labelled Standards
References
FAQ's
References
- Boegesoe, Klaus Peter; Perregaard, Jens, New enantiomers and their isolation, Lundbeck, H., og Co. A/S, Denmark, EP347066B1, June 1, 1989
- Singh, Sonu Sundd; Shah, Hiten; Gupta, Sapna; Jain, Manish; Sharma, Kuldeep; Thakkar, Purav; Shah, Ruchy, Liquid chromatography-electrospray ionisation mass spectrometry method for the determination of escitalopram in human plasma and its application in bioequivalence study, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 811, Issue: 2, Pages: 209-215, 2004
Frequently Asked Questions
Are there specific guidelines for impurity control in different dosage forms of Escitalopram Oxalate, such as tablets or oral solutions?
Regulatory guidelines may provide specific requirements and limits for impurity control in different dosage forms of Escitalopram Oxalate to ensure consistent quality and safety across all formulations.
What are the potential sources of Escitalopram Oxalate impurities?
Impurities in Escitalopram Oxalate can originate from various sources such as starting materials, reagents, solvents, or intermediate degradation during the synthetic process.
What solvent helps in analyzing Escitalopram Oxalate impurities?
Acetonitrile is the solvent for analyzing most of the impurities in Escitalopram Oxalate.
How should Escitalopram Oxalate impurities be stored in terms of temperature?
Escitalopram Oxalate impurities are stored at a controlled room temperature, between 2-8 ⁰C, or according to the specifications provided on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.